Showing 2471-2480 of 2656 results for "".
- EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ for Posterior Segment Uveitis to be Presented at ASRShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-for-posterior-segment-uveitis-to-be-presented-at-asrs/2480032/EyePoint Pharmaceuticals announced that three abstracts supporting the company’s YUTIQ (fluocinolone acetonide intravitreal implant) 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the 36th Annual Scientific Meeting of the American Soci
- Takeda Receives Clearance from the FTC for the Proposed Acquisition of Shirehttps://modernod.com/news/takeda-receives-clearance-from-the-ftc-for-the-proposed-acquisition-of-shire/2480035/Takeda Pharmaceutical announced that it has received unconditional clearance from the United States Federal Trade Commission (FTC) for the proposed acquisition of Shire announced on May 8, 2018. Takeda’s proposed acquisition of Shire is valued at around 46 billion pounds ($60.9 billion).
- Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Diseasehttps://modernod.com/news/ocugen-initiates-phase-3-clinical-trial-of-ocu300-for-the-treatment-of-ocular-graft-versus-host-disease/2480053/Ocugen announced that it has initiated the first of two pivotal, phase 3 clinical trials of OCU300 for the treatment of ocular discomfort and ocular redness in patients with ocular graft versus host disease (oGVHD) following recent acceptance of Ocugen’s investigational new drug (IND) appli
- Market Scope: New Products Poised to Drive Glaucoma Pharma Market to $6.6 Billion by 2023https://modernod.com/news/market-scope-new-products-poised-to-drive-glaucoma-pharma-market-to-6-6-billion-by-2023/2480067/The launches of Vyzulta, Rhopressa, and preservative-free formulations promise to boost manufacturers’ revenues during the next 5 years in the global glaucoma pharmaceuticals market. The upswing follows years of declining revenues as branded products lost patent protection and the market s
- Staar Surgical and Kobe Kanagawa Eye Clinic in Japan Announce Strategic Cooperation Agreementhttps://modernod.com/news/staar-surgical-and-kobe-kanagawa-eye-clinic-in-japan-announce-strategic-cooperation-agreement/2480068/Staar Surgical and Kobe Kanagawa Eye Clinic, with locations in Tokyo and Osaka, announced they have entered into a multi-year Strategic Cooperation Agreement to provide Staar’s EVO Visian ICL lenses as a primary and premium option for patients seeking visual freedom from spectacles and cont
- HelpMeSee Eye Surgery Simulator Demonstrations Scheduled for the 2018 World Ophthalmology Conference in Barcelonahttps://modernod.com/news/helpmesee-eye-surgery-simulator-demonstrations-scheduled-for-the-2018-world-ophthalmology-conference-in-barcelona/2480099/HelpMeSee is presenting their Eye Surgery Simulator and companion eBook for teaching manual small incision cataract surgery (MSICS) at the International Council of Ophthalmology’s (ICO) 2018 World Ophthalmology Conference (WOC) in Barcelona, Spain. WOC attendees interested in scheduling dem
- Group of Takeda Shareholders Call Proposed Shire Purchase “Height of Madness”https://modernod.com/news/group-of-takeda-shareholders-call-proposed-shire-purchase-height-of-madness/2480115/A group of Takeda shareholders have criticized the company’s deal to buy Shire as “the height of madness,” raising concerns over the level of debt that will need to be taken on to fund the purchase, the Financial Times reported. The group hold just over 1 percent of Takeda’
- Allergan Shareholders Urge Company to Overhaul Management Structure; Split Role of Chairman and CEOhttps://modernod.com/news/allergan-shareholders-urge-company-to-overhaul-management-structure-split-role-of-chairman-and-ceo/2480116/In a letter sent to Allergan’s board of directors on Tuesday, two company shareholders, Appaloosa Management and Senator Investment Group, called on the drugmaker to divide the roles of chief executive officer and chairman, currently held by Brent Saunders. The investors also urged Allergan
- FDA Commissioner Scott Gottlieb Proposes Modernization of FDA’s Drug Review Officehttps://modernod.com/news/fda-commissioner-scott-gottlieb-provides-statement-on-proposed-modernization-of-fdas-drug-review-office/2480120/FDA Commissioner Scott Gottlieb, MD, released a statement Monday outlining the agency’s position on a proposed modernization of FDA’s Drug Review Office. The statement reads: “Scientific and medical advances are giving the FDA more opportunities to more fully address diseases a
- Call for Abstracts for Academy 2018 San Antonio Scientific Programhttps://modernod.com/news/call-for-abstracts-for-academy-2018-san-antonio-scientific-program/2480193/The Scientific Program Committee of the American Academy of Optometry invites the submission of abstracts for Academy 2018 San Antonio, to be held Wednesday, November 7 through Saturday, November 10. The Academy’s Scientific Program offers scientists, educators, and clinicians the opportuni